Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers

Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype‐matched drug candidates are often unapproved or off‐label, and improvin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagio, Kanako, Kikuchi, Junko, Takada, Kohichi, Tanabe, Hiroki, Sugiyama, Minako, Ohhara, Yoshihito, Amano, Toraji, Yuki, Satoshi, Komatsu, Yoshito, Osawa, Takahiro, Hatanaka, Kanako C., Hatanaka, Yutaka, Mitamura, Takashi, Yabe, Ichiro, Matsuno, Yoshihiro, Manabe, Atsushi, Sakurai, Akihiro, Ishiguro, Atsushi, Takahashi, Masato, Yokouchi, Hiroshi, Naruse, Hirohito, Mizukami, Yusuke, Dosaka‐Akita, Hirotoshi, Kinoshita, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394138/
https://www.ncbi.nlm.nih.gov/pubmed/37208840
http://dx.doi.org/10.1111/cas.15837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394138/
https://www.ncbi.nlm.nih.gov/pubmed/37208840
http://dx.doi.org/10.1111/cas.15837

Ejemplares similares